EP1444986A1 - Pharmaceutical preparation for the improved treatment of blood-clotting disorders - Google Patents
Pharmaceutical preparation for the improved treatment of blood-clotting disorders Download PDFInfo
- Publication number
- EP1444986A1 EP1444986A1 EP03004900A EP03004900A EP1444986A1 EP 1444986 A1 EP1444986 A1 EP 1444986A1 EP 03004900 A EP03004900 A EP 03004900A EP 03004900 A EP03004900 A EP 03004900A EP 1444986 A1 EP1444986 A1 EP 1444986A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- factor viii
- lrp
- sequence
- seq
- hspg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a pharmaceutical preparation for the improved treatment of blood-clotting disorders containing one or several factor VIII derived peptides which increases the plasma half life of factor VIII. Further, such peptides, their DNA-sequences, their recombinant expression as albumin fusion proteins and vectors containing such DNA-sequences as well as host cells for such recombinant expression vectors and the use of such DNA-sequences in a transfer vector for gene therapy are disclosed.
- haemophilia or haemophilia A is the most common of the inherited bleeding disorders.
- the clinical manifestation of haemophilia A is an abnormal bleeding tendency and before treatment with factor VIII concentrates was introduced the mean life span for a person with severe haemophilia was less than 20 years.
- the use of concentrates of factor VIII from plasma has considerably improved the situation for the haemophilia patients.
- the mean life span has increased extensively, giving most of them the possibility to live a more or less normal life.
- there have been certain problems with the plasma derived concentrates and their use the most serious of which have been the transmission of viruses. So far, viruses causing AIDS, hepatitis B, and non A non B hepatitis have hit the population seriously.
- different virus inactivation methods and new highly purified factor VIII concentrates have recently been developed an inadvertent contamination can not be excluded.
- the factor VIII concentrates are fairly expensive because the limited supply of human plasma raw material.
- a factor VIII product derived from recombinant material is likely to solve a large extent of the problems associated with the use of plasma derived factor VIII concentrates for treatment for haemophilia A.
- the development of a recombinant factor VIII has met with some difficulties, for instance the problem of achieving production levels in sufficiently high yields, in particular regarding the full-length molecule.
- factor VIII In fresh plasma prepared in the presence of protease inhibitors, factor VIII has been shown to have a molecular weight of 280 kDa and to be composed of two polypeptide chains of 200 kDa and 80 kDa, respectively. These chains are held together by metal ion bridges. More or less proteolytically degraded forms of the factor VIII molecule can be found as active fragments in factor VIII material purified from commercial concentrates.
- the fragmented form of factor VIII having molecular weights from 260 kDa down to 170 kDa consists of one heavy chain with a molecular weight ranging from 180 kDa down to 90 kDa, where all variants have identical amino termini, in combination with one 80 kDa light chain.
- the amino-terminal region of the heavy chain is identical to that of the single chain factor VIII polypeptide that can be deduced from the nucleotide sequence data of the factor VIII cDNA.
- the smallest active form of factor VIII with a molecular weight of 170 kDa consisting of one 90 kDa and one 80 kDa chain, can be activated with thrombin to the same extent as the higher molecular weight forms, and thus represents an inactivated form. It has also been shown to have full biological activity in vivo as tested in haemophilia dogs. Thus, the haemostatic effectiveness of the 170 kDa form is the same as for the high molecular weight forms of factor VIII.
- FVIII is secreted into plasma as a heterodimer of a heavy chain (domains A1-A2-B) and a light chain (A3-C1-C2) associated through a noncovalent divalent metal ion linkage between the A1- and A3 domains.
- FVIII is stabilized by binding to von Willebrand factor.
- FVIII Upon proteolytic activation by thrombin, FVIII is activated to a heterotrimer of two heavy chain fragments (A1, a 50 kDa fragment, and A2 a 43 kDa fragment) and the light chain (A3-C1-C2, a 73 kDa fragment).
- the active form of FVIII (FVIIIa) thus consists of an A1-subunit associated through the divalent metal ion linkage to a thrombin-cleaved A3-C1-C2 light chain and a free A2 subunit associated with the A1 domain.
- the dissociation of that free A2 subunit from the heterotrimer is thought to be the rate limiting step in FVIIIa inactivation after thrombin activation.
- Non-activated FVIII has in plasma a half-life of about 14 hours. It is thought that FVIII first binds to heparan sulphate proteoglycans on cell surfaces and then after binding to LRP (low density lipoprotein receptor related protein) is taken up by mainly hepatic cells and catabolised (Ananyeva et al., TCM, Vol. 11, No. 6 (2001) 251 - 257). The contact sites to LRP within FVIII were localized to the A2_site (residues 484 - 509; SEQ ID No. 5) (Saenko et al., J. Biol. Chem.
- FVIII Due to the plasma half life of 14 hours FVIII has to be administered i.v. to haemophilia patients who are on prophylactic treatment about 3 times per week. It would thus be highly desirable to create a FVIII with enhanced plasma half life which could lead to a FVIII preparation which has to be administered less frequently.
- the present invention offers a solution to this problem by blocking the receptors responsible for FVIII catabolism by fragments of FVIII attaching to these receptors or by these fragments fused to human serum albumin.
- Subject of this invention is therefore a pharmaceutical preparation to improve the treatment of blood clotting disorders, which contains a peptide which comprises one or several binding sites for the heparan sulphate proteoglycan (HSPG) and/or the low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence.
- HSPG heparan sulphate proteoglycan
- LRP low density lipoprotein receptor related protein
- Such peptides can be stabilized by fusing or by chemically attaching them to larger plasma proteins with enhanced plasma half-life, preferably to albumin.
- a pharmaceutical preparation may contain a wild-type factor VIII or a coagulation active mutant of factor VIII.
- FVIII is administered separately.
- Such fusion proteins or peptides impair the degradation of factor VIII in plasma and, consequently, increase the half life of factor VIII in plasma because of their capacity to competitively bind to HSPG and/or LRG.
- the reduction of the plasma concentration of said factor VIII-binding compounds reduces the degradation of factor VIII.
- albumin fusion proteins or peptides which are used according to this invention as an ingredient of a pharmaceutical preparation comprise the amino acids 558-565 and/or 484 - 509 of the A2-subunit of the human factor VIII sequence and correspond to the amino acid sequence of SEQ ID No. 1 - No. 6. of the attached sequence listing.
- a thrombin cleavage site was inserted between the albumin and the FVIII fragment portion in a second set of fusion proteins (SEQ ID No. 3 and 4).
- the present invention further comprises a recombinant expression vector containing any of the DNA-sequences disclosed herein as well as host cells being transformed with any of said recombinant expression vectors and the use of said DNA-sequences in a transfer vector for the human gene therapy.
- LRP and LRP/HSPG fragments isolated after BamH1/HindIII digestion and purification from preparative gels, were inserted into an expression vector for C-terminal albumin fusion.
- Plasmid pDB2243 described by Sleep, D., et al. (1991) Bio/Technology 9, 183-187 which contained the yeast PRB1 promoter and the yeast ADH1 terminator providing appropriate transcription terminator sequences as well as the human albumin coding sequence, was used.
- plasmid pDB2243 was digested to completion with BamHI, the recessed ends were blunt ended with T4 DNA polymerase and dNTPs, and finally religated to generate plasmid pDB2566.
- a Glycin-Serin-linker [(GGs) 4 GG] was inserted at the C-terminus of the albumin sequence.
- the resulting plasmid was designated pDB2566GS.
- LRP and LRP/HSPG BamH1/HindIII DNA fragments were isolated from the plasmids described above and ligated with plasmid pDB2566GS, which had partially been digested with Hindlll and then digested to completion with BamHI.
- Resulting plasmid pCN176 contained the LRP
- plasmid pGH159 contained the LRP/HSPG fragment.
- pSAC35 pisintegration plasmid pSAC35 generally disclosed in EP-A-286 424 and described by Sleep, D., et al. (1991) Bio/Technology 9, 183 - 187.
- the Notl albumin-(GGS) 4 GG-LRP expression cassette was isolated from plasmid pCN176, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pCN177 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression of the albumin fusion protein, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- the Notl albumin-(GGS) 4 GG.LRP/HSPG expression cassette was isolated from plasmid pGH159, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pGH165 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression of the albumin fusion protein, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- a thrombin cleavage site was introduced between albumin and the LRP/HSPG and LRP sites, respectively, by inserting a linker into the respective BamH1 sites of plasmids pCN176 and pGH159.
- Resulting plasmids with the linker in correct orientation were designated pCN167 containing the LRP, and pGH168, containing the LRP/HSPG fragments.
- plasmid pSAC35 Appropriate yeast vector sequences were provided by plasmid pSAC35 as described above.
- the Notl albumin(GGS) 4 -TCS-LRP expression cassette was isolated from plasmid pCN167, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pCN169 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression of the albumin fusion protein, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- the Notl albumin-(GGS) 4 -TCS-LRP/HSPG expression cassette was isolated from plasmid pGH168, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pGH171 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- Yeast strains disclosed in WO 95/23857, WO 95/33833 and WO 94/04687 were transformed to leucine prototrophy. The transformants were patched out onto Buffered Minimal Medium and incubated at 30°C until grown sufficiently for further analysis.
- rHA fusions were expressed in shake flask culture and the expression levels were monitored.
- the albumin fusion proteins were purified by cation exchange and gel permeation chromatography. The purified material was then concentrated and diafiltered against PBS.
- the primary objective of the combined pharmacodynamic/pharmacokinetic study is to generate proof for the increase half-life of FVIII, mediated by blocking its uptake and degradation into compartments different from plasma.
- This objective will be achieved by assessing the modulation of pharmacodynamic/pharmacokinetic parameters of FVIII by AFP X (whereas X represents any of the LRP/HSPG albumin fusion proteins described above).
- AFP X represents any of the LRP/HSPG albumin fusion proteins described above.
- the study will be performed in FVIII ko mice. As presumable only one sample per mouse can be collected the study is split into two parts. The first will lead to a suitable dose level of AFP X, while the second will scrutinize on the modulation of the excretion profile by the selected dose level.
- Treatment groups - fixed timepoint No. Treatment Dose / schedule / route n (m/f) 1 FVIII 50 U/kg / single injection / i.v. 5 m + 5 f 2 AFP X 10 mg/kg / single injection / i.v. 5 m + 5 f 3 FVIII + 50 U/kg / single injection / i.v. + 5 m + 5 f AFP X 10 mg/kg / single injection / i.v. 4 FVIII + 50 U/kg / single injection / i.v. + 5 m + 5 f AFP X 100 mg/kg / single injection / i.v.
- mice Five male and five female FVIII ko mice per group will receive FVIII alone or in combination with AFP X at three dose levels (10, 100 or 500 mg/kg) by a single i.v. injection on day 0.
- Blood samples are to be drawn for the determination of the respective antigen or activity levels at the appropriate timepoints.
- the plasma concentration-time profiles of FVIII and potentially AFP X following i.v. injection will analyzed per animal by means of non-linear regression, if applicable.
- An exponential model may be fitted to the baseline-adjusted data by the method of least squares.
- the AUC may be calculated using the linear trapezoidal rule up to the last measured value (AUC 0-end ).
- Treatment group may be a fixed factor. Appropriate contrasts between treatment groups should be evaluated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a pharmaceutical preparation for the improved
treatment of blood-clotting disorders containing one or several factor VIII derived
peptides which increases the plasma half life of factor VIII. Further, such peptides,
their DNA-sequences, their recombinant expression as albumin fusion proteins and
vectors containing such DNA-sequences as well as host cells for such recombinant
expression vectors and the use of such DNA-sequences in a transfer vector for
gene therapy are disclosed.
Description
- The present invention relates to a pharmaceutical preparation for the improved treatment of blood-clotting disorders containing one or several factor VIII derived peptides which increases the plasma half life of factor VIII. Further, such peptides, their DNA-sequences, their recombinant expression as albumin fusion proteins and vectors containing such DNA-sequences as well as host cells for such recombinant expression vectors and the use of such DNA-sequences in a transfer vector for gene therapy are disclosed.
- Classic haemophilia or haemophilia A is the most common of the inherited bleeding disorders. The clinical manifestation of haemophilia A is an abnormal bleeding tendency and before treatment with factor VIII concentrates was introduced the mean life span for a person with severe haemophilia was less than 20 years. The use of concentrates of factor VIII from plasma has considerably improved the situation for the haemophilia patients. The mean life span has increased extensively, giving most of them the possibility to live a more or less normal life. However, there have been certain problems with the plasma derived concentrates and their use, the most serious of which have been the transmission of viruses. So far, viruses causing AIDS, hepatitis B, and non A non B hepatitis have hit the population seriously. Although different virus inactivation methods and new highly purified factor VIII concentrates have recently been developed an inadvertent contamination can not be excluded. Also, the factor VIII concentrates are fairly expensive because the limited supply of human plasma raw material.
- A factor VIII product derived from recombinant material is likely to solve a large extent of the problems associated with the use of plasma derived factor VIII concentrates for treatment for haemophilia A. However, the development of a recombinant factor VIII has met with some difficulties, for instance the problem of achieving production levels in sufficiently high yields, in particular regarding the full-length molecule.
- In fresh plasma prepared in the presence of protease inhibitors, factor VIII has been shown to have a molecular weight of 280 kDa and to be composed of two polypeptide chains of 200 kDa and 80 kDa, respectively. These chains are held together by metal ion bridges. More or less proteolytically degraded forms of the factor VIII molecule can be found as active fragments in factor VIII material purified from commercial concentrates. The fragmented form of factor VIII having molecular weights from 260 kDa down to 170 kDa, consists of one heavy chain with a molecular weight ranging from 180 kDa down to 90 kDa, where all variants have identical amino termini, in combination with one 80 kDa light chain. The amino-terminal region of the heavy chain is identical to that of the single chain factor VIII polypeptide that can be deduced from the nucleotide sequence data of the factor VIII cDNA.
- The smallest active form of factor VIII with a molecular weight of 170 kDa, consisting of one 90 kDa and one 80 kDa chain, can be activated with thrombin to the same extent as the higher molecular weight forms, and thus represents an inactivated form. It has also been shown to have full biological activity in vivo as tested in haemophilia dogs. Thus, the haemostatic effectiveness of the 170 kDa form is the same as for the high molecular weight forms of factor VIII.
- FVIII is secreted into plasma as a heterodimer of a heavy chain (domains A1-A2-B) and a light chain (A3-C1-C2) associated through a noncovalent divalent metal ion linkage between the A1- and A3 domains. In plasma, FVIII is stabilized by binding to von Willebrand factor.
- Upon proteolytic activation by thrombin, FVIII is activated to a heterotrimer of two heavy chain fragments (A1, a 50 kDa fragment, and A2 a 43 kDa fragment) and the light chain (A3-C1-C2, a 73 kDa fragment). The active form of FVIII (FVIIIa) thus consists of an A1-subunit associated through the divalent metal ion linkage to a thrombin-cleaved A3-C1-C2 light chain and a free A2 subunit associated with the A1 domain. The dissociation of that free A2 subunit from the heterotrimer is thought to be the rate limiting step in FVIIIa inactivation after thrombin activation.
Non-activated FVIII has in plasma a half-life of about 14 hours. It is thought that FVIII first binds to heparan sulphate proteoglycans on cell surfaces and then after binding to LRP (low density lipoprotein receptor related protein) is taken up by mainly hepatic cells and catabolised (Ananyeva et al., TCM, Vol. 11, No. 6 (2001) 251 - 257). The contact sites to LRP within FVIII were localized to the A2_site (residues 484 - 509; SEQ ID No. 5) (Saenko et al., J. Biol. Chem. 274 (1999), 37, 685 - 692) and the C2 domain (Lenting et al (1999) J. Biol. Chem., 274; 23, 734-739). Blocking LRP by RAP (receptor associated protein) was shown to increase FVIII levels (Schwarz et al (2000) Blood 95: 1.703 - 1.708). It has been suggested to use RAP to block LRP in order to increase FVIII plasma half life (WO 00/27425) or to vary the FVIII sequence in order to prevent binding to LRP also to increase FVIII half-life (WO 00/28021 and WO 00/71714). - Due to the plasma half life of 14 hours FVIII has to be administered i.v. to haemophilia patients who are on prophylactic treatment about 3 times per week. It would thus be highly desirable to create a FVIII with enhanced plasma half life which could lead to a FVIII preparation which has to be administered less frequently. The present invention offers a solution to this problem by blocking the receptors responsible for FVIII catabolism by fragments of FVIII attaching to these receptors or by these fragments fused to human serum albumin.
- Subject of this invention is therefore a pharmaceutical preparation to improve the treatment of blood clotting disorders, which contains a peptide which comprises one or several binding sites for the heparan sulphate proteoglycan (HSPG) and/or the low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence. Such peptides can be stabilized by fusing or by chemically attaching them to larger plasma proteins with enhanced plasma half-life, preferably to albumin.
- In addition to such a peptide or an albumin fusion protein which comprises one or several binding sites for heparan sulphate proteoglycan (HSPG) and/or low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence said pharmaceutical preparation may contain a wild-type factor VIII or a coagulation active mutant of factor VIII. Alternatively FVIII is administered separately.
- Such fusion proteins or peptides impair the degradation of factor VIII in plasma and, consequently, increase the half life of factor VIII in plasma because of their capacity to competitively bind to HSPG and/or LRG. The reduction of the plasma concentration of said factor VIII-binding compounds reduces the degradation of factor VIII.
- The albumin fusion proteins or peptides which are used according to this invention as an ingredient of a pharmaceutical preparation comprise the amino acids 558-565 and/or 484 - 509 of the A2-subunit of the human factor VIII sequence and correspond to the amino acid sequence of SEQ ID No. 1 - No. 6. of the attached sequence listing.
- Fusing therapeutic proteins to human serum albumin has been shown a means to increase plasma half life (WO 01/77137 . However, it was unclear whether the LRP binding fragment (residue 484 - 509) from FVIII would in an albumin fusion be present in a conformation still allowing the binding to LRP.
- As FVIII binding to LRP is most probably a two step process of first binding to heparan sulphate proteoglycans (HSPG) via residues 558 - 565 (SEQ ID No. 6) and only then to LRP (Ananyeva et al., TCM, Vol. 11, No. 6 (2001) 251 - 257) a fusion protein displaying only the LRP binding site (SEQ ID No. 1) was compared to a fusion protein containing both the LRP and the HSPG binding site (SEQ ID No. 2).
- In order to enable cleavage of the fusion proteins upon FVIII activation by thrombin, a thrombin cleavage site was inserted between the albumin and the FVIII fragment portion in a second set of fusion proteins (SEQ ID No. 3 and 4).
- The present invention further comprises a recombinant expression vector containing any of the DNA-sequences disclosed herein as well as host cells being transformed with any of said recombinant expression vectors and the use of said DNA-sequences in a transfer vector for the human gene therapy.
- Further details of the invention are shown in the following examples:
- LRP binding site and flanking amino acid (amino acids 479 - 517, nomenclature as in Ananyeva et al., TCM, Vol. 11, No. 6 (2001) 251 - 257) was cloned into pLITMUS29 (New England Biolabs) after amplification on a FVIII cDNA containning plasmid using primers We1003 5'GTGGGATCCGGTGGTGGA ATCACTGATGTCCGTCC3' (=SEQ. ID No. 7) and We1059 5'CACAAGCTT ATTATACAGTCACTGTCCATTTATATTTG3' (=SEQ. ID No. 8) (restriction sites used for coning are underlined), subsequent restriction digest with BamH1 and HindIII, purification and ligation into BamH1/HindIII cut pLITMUS29. The resulting plasmid was designated pCN175.
- LRP and HSPG binding site and flanking amino acids (amino acids 479 - 575, nomenclature as in Ananyeva et al., TCM, Vol. 11, No. 6 (2001) 251 - 257) was cloned into pLITMUS29 after amplification on a FVIII cDNA containing plasmid using primers We1003 5'GTGGGATCCGGTGGTGGAATCACTCATGTCCG TCC3' (=SEQ. ID No. 7) and We1004 5'CACAAGCTTATTACAGGATGA CA TTCCTCTTGTC3' (=SEQ. ID No. 9) (restriction sites used for cloning are underlined), subsequent restriction digest with BamH1 and HindIII, purification and ligation into BamH1/HindIII cut pLITMUS29. The resulting plasmid was designated pGH157.
- After clone isolation and sequence verification LRP and LRP/HSPG fragments, isolated after BamH1/HindIII digestion and purification from preparative gels, were inserted into an expression vector for C-terminal albumin fusion.
- Plasmid pDB2243, described by Sleep, D., et al. (1991) Bio/Technology 9, 183-187 which contained the yeast PRB1 promoter and the yeast ADH1 terminator providing appropriate transcription terminator sequences as well as the human albumin coding sequence, was used. First, plasmid pDB2243 was digested to completion with BamHI, the recessed ends were blunt ended with T4 DNA polymerase and dNTPs, and finally religated to generate plasmid pDB2566. Second, a Glycin-Serin-linker [(GGs)4GG] was inserted at the C-terminus of the albumin sequence. For that pDB2566 was digested with Bsu36I and HindIII, and two linker oligonucelotides (GSL+, TTAGGCTTAGGTGGTTCTGGTGGTTCCGGTGGTTCTGGTGGATCC GGTGGA3' (=SEQ. ID No. 10). GSL-, 5'AGCTTCCACCGGATCCACCAGAAC CACCGGAACCACCAGAACCACCTAAGCC3' (=SEQ. ID No. 11) encompassing the (GGS)4GG linker and a BamH1 cloning site were inserted. The resulting plasmid was designated pDB2566GS.
- The LRP and LRP/HSPG BamH1/HindIII DNA fragments were isolated from the plasmids described above and ligated with plasmid pDB2566GS, which had partially been digested with Hindlll and then digested to completion with BamHI. Resulting plasmid pCN176 contained the LRP, plasmid pGH159 contained the LRP/HSPG fragment.
- Appropriate yeast vector sequences were provided by a "disintegration" plasmid pSAC35 generally disclosed in EP-A-286 424 and described by Sleep, D., et al. (1991) Bio/Technology 9, 183 - 187. The Notl albumin-(GGS)4GG-LRP expression cassette was isolated from plasmid pCN176, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pCN177 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression of the albumin fusion protein, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- The Notl albumin-(GGS)4GG.LRP/HSPG expression cassette was isolated from plasmid pGH159, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pGH165 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression of the albumin fusion protein, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- A thrombin cleavage site (TCS) was introduced between albumin and the LRP/HSPG and LRP sites, respectively, by inserting a linker into the respective BamH1 sites of plasmids pCN176 and pGH159. For that the plasmids pCN176 and pGH159 were linearized with BamH1 and, after dephosphorylation, ligated together with a hybridized linker consisting of 5'-phosphorylated oligonucleotides 5'GATCTCTAGTTCCACGTG 3' (=SEQ. ID No. 12) and 5'GATCCACGTGGAACTAGA3' (=SEQ. ID No. 13). Resulting plasmids with the linker in correct orientation (see figure below =SEQ. ID No. 14 and 15) were designated pCN167 containing the LRP, and pGH168, containing the LRP/HSPG fragments.
- Appropriate yeast vector sequences were provided by plasmid pSAC35 as described above. The Notl albumin(GGS)4-TCS-LRP expression cassette was isolated from plasmid pCN167, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pCN169 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression of the albumin fusion protein, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- The Notl albumin-(GGS)4-TCS-LRP/HSPG expression cassette was isolated from plasmid pGH168, purified and ligated into Notl digested pSAC35 which had been treated with calf intestinal phosphatase, creating two plasmids; the first pGH171 contained the Notl expression cassette in the same expression orientation as LEU2 and was used for expression, while the second contained the Notl expression cassette in the opposite orientation to LEU2.
- Yeast strains disclosed in WO 95/23857, WO 95/33833 and WO 94/04687 were transformed to leucine prototrophy. The transformants were patched out onto Buffered Minimal Medium and incubated at 30°C until grown sufficiently for further analysis.
- rHA fusions were expressed in shake flask culture and the expression levels were monitored. The albumin fusion proteins were purified by cation exchange and gel permeation chromatography. The purified material was then concentrated and diafiltered against PBS.
- The primary objective of the combined pharmacodynamic/pharmacokinetic study is to generate proof for the increase half-life of FVIII, mediated by blocking its uptake and degradation into compartments different from plasma.
- This objective will be achieved by assessing the modulation of pharmacodynamic/pharmacokinetic parameters of FVIII by AFP X (whereas X represents any of the LRP/HSPG albumin fusion proteins described above). As endogenous levels of FVIII might flaw the selected endpoint, the study will be performed in FVIII ko mice. As presumable only one sample per mouse can be collected the study is split into two parts. The first will lead to a suitable dose level of AFP X, while the second will scrutinize on the modulation of the excretion profile by the selected dose level.
- To assess the half-life and bioavailability of FVIII versus FVIII co-infused with LRP albumin-fusion-protein X, by means of determining plasma levels and by determining haemostasis in the tail cut bleeding model. Bleeding time assessment might deliver a more accurate reflection of FVIII levels as compared to antigen levels.
- To potentially assess additional pharmacokinetic parameters of FVIII versus FVIII coinfused with LRP fusion-protein X.
-
Treatment groups - fixed timepoint No. Treatment Dose / schedule / route n (m/f) 1 FVIII 50 U/kg / single injection / i.v. 5 m + 5 f 2 AFP X 10 mg/kg / single injection / i.v. 5 m + 5 f 3 FVIII + 50 U/kg / single injection / i.v. + 5 m + 5 f AFP X 10 mg/kg / single injection / i.v. 4 FVIII + 50 U/kg / single injection / i.v. + 5 m + 5 f AFP X 100 mg/kg / single injection / i.v. 5 FVIII + 50 U/kg / single injection / i.v. + 5 m + 5 f AFP X 500 mg/kg /single injection / i.v. Treatment groups - fixed dose No. Treatment Dose / schedule / route Sampling timepoint n (m/f) 1 FVIII 50 U/kg / single injection / i.v. 5 hours 5 m + 5 f 2 AFP X x mg/KG / single injection / i.v. 5 hours 5 m + 5 f 3 FVIII + 50 U/kg / single injection / i.v. + 5 hours 5 m + 5 f AFP X x mg/kg / single injection / i.v. 4 FVIII 50 U/kg / single injection / i.v. 1 day 5 m + 5 f 5 AFP X x mg/kg / single injection / i.v. 1 day 5 m + 5 f 6 FVIII + 50 U/kg / single injection / i.v. + 1 day 5 m + 5 f AFP X x mg/kg / single injection / i.v. -
Test article 1 AFP X Manufacturer Aventis Behring GmbH, Lab Thomas Weimer Batch No. tbd Application volume tbd Single dose/route 10, 100 or 500 mg/kg, i.v. Frequency 1 × (t = 0) Test article 2 Helixate or a suitable other FVIII concentrate Manufacturer Aventis Behring GmbH Batch No. tbd Application volume tbd Single dose/route 50 U/kg, i.v. Frequency 1 × (t = 0) -
Species /Strain C57BI6 Mouse, FVIII-ko Sex/Age 55 male / 55 female No. total 110 Supplier Charles River, Kisslegg - Five male and five female FVIII ko mice per group will receive FVIII alone or in combination with AFP X at three dose levels (10, 100 or 500 mg/kg) by a single i.v. injection on day 0.
- Blood samples are to be drawn for the determination of the respective antigen or activity levels at the appropriate timepoints.
- Pharmacokinetic (PK) variables, depending on the frequency of samples:
- Half-lives, area under the plasma concentration time curve up to the last plasma sample (AUC0-and), maximum concentration (Cmax), time to maximum concentration (tmax).
-
- Pharmacodynamic endpoints:
- Tail cut bleeding time, blood loss with cut off value of 10 min. The bleeding time will be determined in anaesthesia.
-
- The plasma concentration-time profiles of FVIII and potentially AFP X following i.v. injection will analyzed per animal by means of non-linear regression, if applicable. An exponential model may be fitted to the baseline-adjusted data by the method of least squares.
- The AUC may be calculated using the linear trapezoidal rule up to the last measured value (AUC 0-end).
- Individual PK results will summarized descriptively per treatment (minimum, median, maximum, mean, standard deviation), completed by a two-way analysis of variance was carried out for the following variables: elimination half-life, AUC and Cmax (all log-transformed). Treatment group may be a fixed factor. Appropriate contrasts between treatment groups should be evaluated.
-
- SEQ ID No.1 represents the LRP binding site fused to human albumin. 1-24, leader sequence, which is removed during secretion in yeast; 25-609, human albumin; 610-623, GGS linker; 624-662, LRP binding site (629-654) and additional FVIII derived flanking sequences (624-628; 655-662).
- SEQ ID No.2 represents the LRP/HSPG binding sites fused to human albumin. 1-24, leader sequence, which is removed during secretion in yeast; 25-609, human albumin; 610-623, GGS linker; 624-720, LRP and HSPG binding sites within the FVIII context; LRP binding site (629-654), HSPG binding site (703-710).
- SEQ ID No.3 represents the LRP binding site fused to human albumin, including an additional thrombin cleavage site. 1-24, leader sequence, which is removed during secretion in yeast; 25-609, human albumin; 610-621, GGS linker; 622-668, LRP binding site (635-660) and additional FVIII derived flanking sequences (630-634; 661-668); 625/626, thrombin cleavage site.
- SEQ ID No.4 represents the LRP/HSPG binding sites fused to human albumin, including an additional thrombin cleavage site. 1-24, leader sequence, which is removed during secretion in yeast; 25-609, human albumin; 610-621, GGS linker; 630-726, LRP and HSPG binding sites within the FVIII context; LRP binding site (635-660), HSPG binding site (709-716); 625/626, thrombin cleavage site.
- SEQ ID No.5 shows the contact sites to LRP within the Factor VIII A2 domain, amino acids residues 484 - 509.
- SEQ ID No.6 shows the HSPG binding sites within the Factor VIII A2 domain, amino acids residues 558 - 565.
- SEQ ID No.7 to 9 represent synthetic oligonucleotides used for cloning the LRP and LRP/HSPG binding sites.
- SEQ ID No.10 and 11 represent synthetic oligonucleotides used for modification of the yeast vector pDB2243.
- SEQ ID No.12 and 13 represent synthetic oligonucleotides used for introduction of a thrombin cleavage site.
- SEQ ID No. 14 and 15 display the junction of albumin and LRP binding site with inserted GGS linker and thrombin cleavage site within plasmids pCN167 and pGH168.
-
Claims (12)
- Pharmaceutical preparation to improve the treatment of blood-clotting disorders, characterised in that it contains a peptide which comprises one or several binding sites for the heparan sulphate proteoglycan (HSPG) and/or the low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence.
- Pharmaceutical preparation as claimed in claim 1, characterised in that it contains in addition to the peptide comprising one or several binding sites for heparan sulphate proteoglycan (HSPG) and/or low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence a wild-type factor VIII or a coagulation active mutant of factor VIII.
- Peptide characterised in that it contains one or several binding sites for heparan sulphate proteoglycan (HSPG) and/or low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence.
- Peptide as claimed in claim 3, characterised in that it contains the amino acids 558 - 565 and/or 484 - 509 of the A2-subunit of the human factor VIII sequence.
- Albumin fusion protein, characterised in that it contains one ore several binding sites for heparan sulphate proteoglycan (HSPG) and/or low density lipoprotein receptor related protein (LRP) of the human factor VIII sequence.
- Albumin fusion protein as claimed in claim 5, characterised in that it contains the amino acids 558 - 565 and/or 484 - 509 of the A2-subunit of the human factor VIII sequence.
- Albumin fusion protein as claimed in claims 5 and 6, characterised in that it contains a thrombin cleavage site between the albumin sequence and the human factor VIII sequence.
- Albumin fusion protein as claimed in claims 5 to 7, characterised in that it contains the amino acid sequence of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 or SEQ ID No.4 of the attached sequence listing.
- DNA sequence coding for any of the amino acid sequences of claims 3 to 8.
- Recombinant expression vector containing any of the DNA sequences of claim 9.
- Host cells being transformed with a recombinant expression vectors of claim 10.
- Use of any of the DNA sequences of claim 9 in a transfer vector for the human gene therapy.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03004900A EP1444986A1 (en) | 2003-02-07 | 2003-03-06 | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
EP04000589A EP1454632A1 (en) | 2003-02-07 | 2004-01-14 | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
CA002457105A CA2457105A1 (en) | 2003-02-07 | 2004-02-05 | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
KR1020040007898A KR20040072463A (en) | 2003-02-07 | 2004-02-06 | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
AU2004200423A AU2004200423A1 (en) | 2003-02-07 | 2004-02-06 | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
JP2004030232A JP2004236661A (en) | 2003-02-07 | 2004-02-06 | Pharmaceutical preparation for improved treatment of blood-clotting disorder |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03002598 | 2003-02-07 | ||
EP03002598 | 2003-02-07 | ||
EP03004900A EP1444986A1 (en) | 2003-02-07 | 2003-03-06 | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1444986A1 true EP1444986A1 (en) | 2004-08-11 |
Family
ID=32658196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03004900A Withdrawn EP1444986A1 (en) | 2003-02-07 | 2003-03-06 | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1444986A1 (en) |
JP (1) | JP2004236661A (en) |
KR (1) | KR20040072463A (en) |
AU (1) | AU2004200423A1 (en) |
CA (1) | CA2457105A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2007144173A1 (en) * | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
WO2008077616A1 (en) * | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
US20130108629A1 (en) * | 2009-12-06 | 2013-05-02 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
AU2013202566B2 (en) * | 2006-06-14 | 2016-05-05 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2018193033A1 (en) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2007885T3 (en) * | 2006-04-11 | 2010-12-31 | Csl Behring Gmbh | Method of increasing the in vivo recovery of therapeutic polypeptides |
EP2291523B1 (en) * | 2008-06-24 | 2014-12-17 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
WO2000071714A2 (en) * | 1999-05-24 | 2000-11-30 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
WO2002060951A2 (en) * | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
-
2003
- 2003-03-06 EP EP03004900A patent/EP1444986A1/en not_active Withdrawn
-
2004
- 2004-02-05 CA CA002457105A patent/CA2457105A1/en not_active Abandoned
- 2004-02-06 AU AU2004200423A patent/AU2004200423A1/en not_active Abandoned
- 2004-02-06 KR KR1020040007898A patent/KR20040072463A/en not_active Application Discontinuation
- 2004-02-06 JP JP2004030232A patent/JP2004236661A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
WO2000071714A2 (en) * | 1999-05-24 | 2000-11-30 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
WO2002060951A2 (en) * | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
Non-Patent Citations (2)
Title |
---|
LENTING PETER J ET AL: "The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 34, 20 August 1999 (1999-08-20), pages 23734 - 23739, XP002233162, ISSN: 0021-9258 * |
SARAFANOV ANDREI G ET AL: "Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 15, 13 April 2001 (2001-04-13), pages 11970 - 11979, XP002233161, ISSN: 0021-9258 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
EP3564267A1 (en) * | 2006-06-14 | 2019-11-06 | CSL Behring GmbH | Proteolytically cleavable fusion proteins with high molar specific activity |
EP2256135B1 (en) | 2006-06-14 | 2019-03-13 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP3896090A1 (en) * | 2006-06-14 | 2021-10-20 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
KR20090023486A (en) * | 2006-06-14 | 2009-03-04 | 체에스엘 베링 게엠베하 | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP2256135A1 (en) * | 2006-06-14 | 2010-12-01 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
AU2007260185B2 (en) * | 2006-06-14 | 2013-01-31 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP3564267B1 (en) | 2006-06-14 | 2021-03-17 | CSL Behring GmbH | Proteolytically cleavable fusion proteins with high molar specific activity |
EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
AU2013202566B2 (en) * | 2006-06-14 | 2016-05-05 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
AU2013202566C1 (en) * | 2006-06-14 | 2018-07-12 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2007144173A1 (en) * | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP3231440A1 (en) * | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
WO2008077616A1 (en) * | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
US20130108629A1 (en) * | 2009-12-06 | 2013-05-02 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof |
US9050318B2 (en) * | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
US11266720B2 (en) | 2009-12-06 | 2022-03-08 | Bioverativ Therapeutics Inc. | Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof |
US9241978B2 (en) | 2009-12-06 | 2016-01-26 | Biogen Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
WO2018193033A1 (en) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
CN110770251A (en) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | Method for purifying albumin fusion proteins |
US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
Also Published As
Publication number | Publication date |
---|---|
AU2004200423A1 (en) | 2004-08-26 |
KR20040072463A (en) | 2004-08-18 |
CA2457105A1 (en) | 2004-08-07 |
JP2004236661A (en) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102659212B1 (en) | Factor IX fusion protein and methods of making and using the same | |
KR970002915B1 (en) | Novel proteins with factor vñ activity, process for their preparation using genetically-engineered cells | |
Lind et al. | Novel forms of B‐domain‐deleted recombinant factor VIII molecules: construction and biochemical characterization | |
JP3964622B2 (en) | Modified factor VIII | |
AU610059B2 (en) | Method of producing a recombinant protein complex having human factor VIII:C activity | |
EP0527821B1 (en) | Oxidation resistant thrombomodulin analogs | |
IE850998L (en) | Cloned factor viii | |
WO1990013306A2 (en) | Small polypeptides | |
AU2001292861A1 (en) | Modified factor VIII | |
JP4634036B2 (en) | Nucleic acid and amino acid sequences encoding high level expressor factor VIII polypeptides and methods of use | |
EP1444986A1 (en) | Pharmaceutical preparation for the improved treatment of blood-clotting disorders | |
CA2130900C (en) | Therapeutic domains of von willebrand factor | |
JP2005518783A5 (en) | ||
JP2005511038A (en) | Variant of factor VIII C2 domain | |
JP2872255B2 (en) | High yield production method of factor VIII | |
JPH05500615A (en) | Hirudin and new recombinant production method of hirudin | |
EP1454632A1 (en) | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides | |
CN104926946B (en) | ADAMTS13-MDTCS fusion protein with function of prolonging half-life in vivo and application thereof | |
CN110831613A (en) | Factor IX fusion proteins and methods of making and using same | |
US20220259287A1 (en) | Single chain factor viii molecule | |
WO1992017192A1 (en) | Therapeutic fragments of von willebrand factor | |
US7084251B1 (en) | Methods and Deoxyribonucleic acid for the preparation of tissue factor protein | |
WO1992006999A1 (en) | Therapeutic fragments of von willebrand factor | |
CA2261183A1 (en) | Adenoviral transfer vector for the gene transport of a dna sequence | |
US7049131B1 (en) | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ZLB BEHRING GMBH |
|
AKX | Designation fees paid | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050212 |